Viking Therapeutics, Inc. (VKTX)
| Market Cap | 3.42B -17.0% |
| Revenue (ttm) | n/a |
| Net Income | -627.20M |
| EPS | -5.41 |
| Shares Out | 127.52M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,668,175 |
| Open | 25.81 |
| Previous Close | 25.79 |
| Day's Range | 25.55 - 27.03 |
| 52-Week Range | 23.82 - 43.15 |
| Beta | 0.75 |
| Analysts | Strong Buy |
| Price Target | 95.32 (+255.14%) |
| Earnings Date | Oct 28, 2026 |
About VKTX
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II c... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 21 analysts, the average rating for VKTX stock is "Strong Buy." The 12-month stock price target is $95.32, which is an increase of 255.14% from the latest price.
News
Viking Therapeutics to Participate at Upcoming Investor Conferences
SAN DIEGO, Nov. 3, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and ...
Viking Therapeutics price target raised to $118 from $106 at Canaccord
Canaccord raised the firm’s price target on Viking Therapeutics (VKTX) to $118 from $106 and keeps a Buy rating on the shares. The firm said they reported financial results and…
Viking Therapeutics price target lowered to $34 from $38 at Goldman Sachs
Goldman Sachs analyst Richard Law lowered the firm’s price target on Viking Therapeutics (VKTX) to $34 from $38 and keeps a Neutral rating on the shares.
Viking Therapeutics Earnings Call Transcript: Q3 2026
VK2735 advanced into four Phase III obesity studies, while maintenance data supported less frequent dosing as a potential differentiator. Q3 net loss was $183.2M, and $960M in cash and short-term investments followed a $575M gross financing.
Viking Therapeutics Earnings release: Q3 2026
Viking Therapeutics released its Q3 2026 earnings on October 28, 2026, summarizing the period's financial results.
Viking Therapeutics Quarterly report: Q3 2026
Viking Therapeutics has published its Q3 2026 quarterly earnings report on October 28, 2026.
Viking Therapeutics reports Q3 EPS ($1.55), consensus ($1.06)
At September 30, Viking held cash, cash equivalents, and short-term investments of $960M vs. $706M as of December 31, 2025. “During Q3, Viking continued to advance and expand development activities…
Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
-- VANQUISH Phase 3 Trials for Subcutaneous VK2735 in Obesity Continue to Advance -- -- SUNRISE Phase 3 Trials for Oral VK2735 Initiated -- -- Positive Top-Line Results Announced for VK2735 Maintena...
Viking Therapeutics put volume heavy and directionally bearish
Bearish flow noted in Viking Therapeutics (VKTX) with 6,553 puts trading, or 1.6x expected. Most active are Nov-26 20 puts and Nov-26 21 puts, with total volume in those strikes…
Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026
Conference Call Scheduled for Wednesday, October 28, at 4:30 p.m. Eastern Time SAN DIEGO, Oct. 21, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharma...
Viking Therapeutics price target lowered to $106 from $114 at Canaccord
Canaccord lowered the firm’s price target on Viking Therapeutics (VKTX) to $106 from $114 and keeps a Buy rating on the shares. The firm updated its model to incorporate MFN…
Viking Therapeutics Slides: Corporate presentation
Viking Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 17, 2026.
Viking Therapeutics initiated with a Buy at UBS
UBS initiated coverage of Viking Therapeutics (VKTX) with a Buy rating and $94 price target The company is developing VK2735 as both injectable and oral obesity drugs, and data point…
Viking Therapeutics initiated with a Buy at UBS
UBS analyst Joon Lee initiated coverage of Viking Therapeutics (VKTX) with a Buy rating and $94 price target Viking is developing VK2735 as both injectable and oral obesity drugs, notes…
Viking Therapeutics begins Sunrise Phase 3 clinical program
Viking Therapeutics (VKTX) announced the initiation of the SUNRISE Phase 3 clinical program for oral VK2735, the company’s dual agonist of the glucagon-like peptide 1, or GLP-1, and glucose-dependent ...
Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity
SUNRISE -1 and SUNRISE-2 Studies to Evaluate Oral VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a...
Viking Therapeutics price target lowered to $85 from $87 at Truist
Truist analyst Gregory Renza lowered the firm’s price target on Viking Therapeutics (VKTX) to $85 from $87 and keeps a Buy rating on the shares as part of a broader…
Viking Therapeutics initiates oral maintenance dosing study of VK2735
Viking Therapeutics (VKTX) announced the initiation of an exploratory oral maintenance dosing study of VK2735, the company’s dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinot...
Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity
Study to Explore Oral Maintenance Dosing Regimens Following Initial Weight Loss with Subcutaneous VK2735 Monthly and Every-Other-Week Subcutaneous Regimens to also be Evaluated SAN DIEGO, Oct. 6, 2026...
3 Best Growth Stocks to Buy Now with 55%+ Upside, According to Analysts
Growth stocks can offer strong return potential when their businesses continue to expand. Viking Therapeutics ($VKTX), AeroVironment ($AVAV), and Ondas ($ONDS) stand out with Strong Buy ratings from a...
Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes
Gross Proceeds to Viking Approximately $575 Million SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the develo...
Viking Therapeutics falls -14.0%
Viking Therapeutics (VKTX) is down -14.0%, or -$5.82 to $35.83.
Viking Therapeutics falls -13.1%
Viking Therapeutics (VKTX) is down -13.1%, or -$5.46 to $36.19.
Viking Therapeutics 7.86M share Spot Secondary priced at $35.00
Morgan Stanley and JPMorgan are acting as joint book running managers for the offering. The deal size was increased to $225M from $200M and priced at the low end of…
Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes
SAN DIEGO, Sept. 24, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine...